Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With Dyslipidemia.

Olson EJ, Mahar KM, Haws TF, Fossler MJ, Gao F, de Gouville AC, Sprecher DL, Lepore JJ.

Clin Pharmacol Drug Dev. 2019 Oct;8(7):871-883. doi: 10.1002/cpdd.704. Epub 2019 Jul 3.

PMID:
31268250
2.

The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure.

Cooper LB, Lippmann SJ, DiBello JR, Gorsh B, Curtis LH, Sikirica V, Hernandez AF, Sprecher DL, Laskey WK, Saini R, Fonarow GC, Hammill BG.

Am J Cardiol. 2019 Aug 15;124(4):545-553. doi: 10.1016/j.amjcard.2019.05.030. Epub 2019 May 25.

PMID:
31208702
3.

Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects.

Goyal N, Skrdla P, Schroyer R, Kumar S, Fernando D, Oughton A, Norton N, Sprecher DL, Cheriyan J.

Am J Cardiovasc Drugs. 2019 Jun;19(3):335-342. doi: 10.1007/s40256-018-00320-6.

PMID:
30637626
4.

Nosebleeds in hereditary hemorrhagic telangiectasia: Development of a patient-completed daily eDiary.

Clark M, Berry P, Martin S, Harris N, Sprecher D, Olitsky S, Hoag JB.

Laryngoscope Investig Otolaryngol. 2018 Nov 14;3(6):439-445. doi: 10.1002/lio2.211. eCollection 2018 Dec.

5.

Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia.

Faughnan ME, Gossage JR, Chakinala MM, Oh SP, Kasthuri R, Hughes CCW, McWilliams JP, Parambil JG, Vozoris N, Donaldson J, Paul G, Berry P, Sprecher DL.

Angiogenesis. 2019 Feb;22(1):145-155. doi: 10.1007/s10456-018-9646-1. Epub 2018 Sep 6.

6.

Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire.

Mathias SD, Vallow S, Gipson DS, Thorneloe KS, Sprecher D.

Am J Kidney Dis. 2017 Oct;70(4):532-540. doi: 10.1053/j.ajkd.2017.04.023. Epub 2017 Jun 26.

PMID:
28663063
7.

Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.

Kim YH, Kim MJ, Choe SW, Sprecher D, Lee YJ, P Oh S.

J Thromb Haemost. 2017 Jun;15(6):1095-1102. doi: 10.1111/jth.13683. Epub 2017 May 3.

8.

Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist.

Sprecher D, Maxwell M, Goodman J, White B, Tang CM, Boullay V, de Gouville AC.

Eur J Pharmacol. 2015 Jun 5;756:1-7. doi: 10.1016/j.ejphar.2015.01.051. Epub 2015 Mar 12.

PMID:
25773497
9.

A low-frequency variant in MAPK14 provides mechanistic evidence of a link with myeloperoxidase: a prognostic cardiovascular risk marker.

Waterworth DM, Li L, Scott R, Warren L, Gillson C, Aponte J, Sarov-Blat L, Sprecher D, Dupuis J, Reiner A, Psaty BM, Tracy RP, Lin H, McPherson R, Chissoe S, Wareham N, Ehm MG.

J Am Heart Assoc. 2014 Aug 27;3(4). pii: e001074. doi: 10.1161/JAHA.114.001074.

10.

On computational algorithms for real-valued continuous functions of several variables.

Sprecher D.

Neural Netw. 2014 Nov;59:16-22. doi: 10.1016/j.neunet.2014.05.015. Epub 2014 Jun 26.

PMID:
25036646
11.

Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.

Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, Cai G, de Winter RJ, Hamm CW, Heitner JF, Kim R, Lerman A, Patel MR, Tanguay JF, Lepore JJ, Al-Khalidi HR, Sprecher DL, Granger CB; SOLSTICE Investigators.

Lancet. 2014 Sep 27;384(9949):1187-95. doi: 10.1016/S0140-6736(14)60417-7. Epub 2014 Jun 12. Erratum in: Lancet. 2014 Sep 27;384(9949):1186.

PMID:
24930728
12.

Observation of g/u-symmetry mixing in the high-n Rydberg states of HD.

Sprecher D, Merkt F.

J Chem Phys. 2014 Mar 28;140(12):124313. doi: 10.1063/1.4868024.

PMID:
24697447
13.

Determination of the binding energies of the np Rydberg states of H2, HD, and D2 from high-resolution spectroscopic data by multichannel quantum-defect theory.

Sprecher D, Jungen C, Merkt F.

J Chem Phys. 2014 Mar 14;140(10):104303. doi: 10.1063/1.4866809. Erratum in: J Chem Phys. 2014 Jun 14;140(22):229904.

PMID:
24628165
14.

High-resolution spectroscopy and quantum-defect model for the gerade triplet np and nf Rydberg states of He2.

Sprecher D, Liu J, Krähenmann T, Schäfer M, Merkt F.

J Chem Phys. 2014 Feb 14;140(6):064304. doi: 10.1063/1.4864002.

PMID:
24527912
15.

Platelet aggregation unchanged by lipoprotein-associated phospholipase A₂ inhibition: results from an in vitro study and two randomized phase I trials.

Shaddinger BC, Xu Y, Roger JH, Macphee CH, Handel M, Baidoo CA, Magee M, Lepore JJ, Sprecher DL.

PLoS One. 2014 Jan 27;9(1):e83094. doi: 10.1371/journal.pone.0083094. eCollection 2014.

16.
17.

Spectrum of the autoionizing triplet gerade Rydberg states of H2 and its analysis using multichannel quantum-defect theory.

Sprecher D, Jungen C, Merkt F.

J Phys Chem A. 2013 Oct 3;117(39):9462-76. doi: 10.1021/jp311793t. Epub 2013 Mar 27.

PMID:
23428200
18.

Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.

Barbour AM, Sarov-Blat L, Cai G, Fossler MJ, Sprecher DL, Graggaber J, McGeoch AT, Maison J, Cheriyan J.

Br J Clin Pharmacol. 2013 Jul;76(1):99-106. doi: 10.1111/bcp.12063.

19.

The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale.

Melloni C, Sprecher DL, Sarov-Blat L, Patel MR, Heitner JF, Hamm CW, Aylward P, Tanguay JF, DeWinter RJ, Marber MS, Lerman A, Hasselblad V, Granger CB, Newby LK.

Am Heart J. 2012 Nov;164(5):646-653.e3. doi: 10.1016/j.ahj.2012.07.030. Epub 2012 Oct 16.

PMID:
23137494
20.

Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, Collier DJ, Marber MS, Choudhury RP, Fayad ZA, Tawakol A, Gleeson FV, Lepore JJ, Davis B, Willette RN, Wilkinson IB, Sprecher DL, Cheriyan J.

JACC Cardiovasc Imaging. 2012 Sep;5(9):911-22. doi: 10.1016/j.jcmg.2012.02.016.

21.

Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.

Olson EJ, Pearce GL, Jones NP, Sprecher DL.

Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2289-94. doi: 10.1161/ATVBAHA.112.247890. Epub 2012 Jul 19.

PMID:
22814748
22.

Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations.

Ooi EM, Russell BS, Olson E, Sun SZ, Diffenderfer MR, Lichtenstein AH, Keilson L, Barrett PH, Schaefer EJ, Sprecher DL.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):459-66. doi: 10.1161/ATVBAHA.111.238493. Epub 2011 Nov 17.

23.

Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.

Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH.

J Clin Endocrinol Metab. 2011 Oct;96(10):E1568-76. doi: 10.1210/jc.2011-1131. Epub 2011 Aug 3.

24.

Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.

Cheriyan J, Webb AJ, Sarov-Blat L, Elkhawad M, Wallace SM, Mäki-Petäjä KM, Collier DJ, Morgan J, Fang Z, Willette RN, Lepore JJ, Cockcroft JR, Sprecher DL, Wilkinson IB.

Circulation. 2011 Feb 8;123(5):515-23. doi: 10.1161/CIRCULATIONAHA.110.971986. Epub 2011 Jan 24.

PMID:
21262998
25.

Towards measuring the ionisation and dissociation energies of molecular hydrogen with sub-MHz accuracy.

Sprecher D, Jungen C, Ubachs W, Merkt F.

Faraday Discuss. 2011;150:51-70; discussion 113-60.

PMID:
22457944
26.

Communication: The ionization and dissociation energies of HD.

Sprecher D, Liu J, Jungen C, Ubachs W, Merkt F.

J Chem Phys. 2010 Sep 21;133(11):111102. doi: 10.1063/1.3483462.

PMID:
20866117
27.

Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans.

Sarov-Blat L, Morgan JM, Fernandez P, James R, Fang Z, Hurle MR, Baidoo C, Willette RN, Lepore JJ, Jensen SE, Sprecher DL.

Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2256-63. doi: 10.1161/ATVBAHA.110.209205. Epub 2010 Aug 5.

PMID:
20689074
28.

Determination of the ionization and dissociation energies of the deuterium molecule (D(2)).

Liu J, Sprecher D, Jungen C, Ubachs W, Merkt F.

J Chem Phys. 2010 Apr 21;132(15):154301. doi: 10.1063/1.3374426.

PMID:
20423175
29.

Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man.

Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F.

J Clin Endocrinol Metab. 2009 Sep;94(9):3594-601. doi: 10.1210/jc.2009-0111. Epub 2009 Jun 16.

PMID:
19531592
30.

Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.

Potter LK, Sprecher DL, Walker MC, Tobin FL.

J Lipid Res. 2009 Nov;50(11):2222-34. doi: 10.1194/jlr.M900015-JLR200. Epub 2009 Mar 11.

31.

Effect of hCG treatment on the oestrous and ovulation responses to FSH in prepubertal gilts.

Manjarin R, Dominguez JC, Castro MJ, Sprecher DJ, Cassar G, Friendship RM, Kirkwood RN.

Reprod Domest Anim. 2009 Jun;44(3):432-4. doi: 10.1111/j.1439-0531.2008.01103.x. Epub 2008 Nov 9.

PMID:
19000224
32.

Effect of eCG or eCG Plus hCG on oestrus expression and ovulation in prepubertal gilts.

Manjarin R, Cassar G, Sprecher DJ, Friendship RM, Dominguez JC, Kirkwood RN.

Reprod Domest Anim. 2009 Jun;44(3):411-3. doi: 10.1111/j.1439-0531.2008.01089.x. Epub 2008 Oct 9.

PMID:
18954389
33.

Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease.

Shishehbor MH, Oliveira LP, Lauer MS, Sprecher DL, Wolski K, Cho L, Hoogwerf BJ, Hazen SL.

Am J Cardiol. 2008 Jun 15;101(12):1741-6. doi: 10.1016/j.amjcard.2008.02.060. Epub 2008 Apr 9.

34.

Effect of prior FSH treatment on the estrus and ovulation responses to eCG in prepubertal gilts.

Manjarin R, Dominguez JC, Castro MJ, Vallado B, Rodriguez S, Sprecher DJ, Cassar G, Friendship RM, Kirkwood RN.

Anim Reprod Sci. 2009 Jan;110(1-2):123-7. doi: 10.1016/j.anireprosci.2008.01.001. Epub 2008 Jan 15.

PMID:
18282669
35.

Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta.

Sprecher DL.

Am J Cardiol. 2007 Dec 3;100(11 A):n20-4. Review.

PMID:
18047848
36.

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F.

Diabetes. 2008 Feb;57(2):332-9. Epub 2007 Nov 16.

37.

Effect of insemination-ovulation interval and addition of seminal plasma on sow fertility to insemination of cryopreserved sperm.

Abad M, Garcia JC, Sprecher DJ, Cassar G, Friendship RM, Buhr MM, Kirkwood RN.

Reprod Domest Anim. 2007 Aug;42(4):418-22.

PMID:
17635780
38.

Effect of sperm cryopreservation and supplementing semen doses with seminal plasma on the establishment of a sperm reservoir in gilts.

Abad M, Sprecher DJ, Ross P, Friendship RM, Kirkwood RN.

Reprod Domest Anim. 2007 Apr;42(2):149-52.

PMID:
17348971
39.

Predominance of a proinflammatory phenotype in monocyte-derived macrophages from subjects with low plasma HDL-cholesterol.

Sarov-Blat L, Kiss RS, Haidar B, Kavaslar N, Jaye M, Bertiaux M, Steplewski K, Hurle MR, Sprecher D, McPherson R, Marcel YL.

Arterioscler Thromb Vasc Biol. 2007 May;27(5):1115-22. Epub 2007 Feb 22.

PMID:
17322100
40.

Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.

Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson TM, Hassall DG, Ancellin N, Patterson SD, Lobe DC, Johnson TG.

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):359-65. Epub 2006 Nov 16.

PMID:
17110604
41.

Skin cholesterol adds to Framingham risk assessment.

Sprecher DL, Pearce GL.

Am Heart J. 2006 Oct;152(4):694-6.

PMID:
16996840
42.
44.

The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events.

Koro CE, Bowlin SJ, Stump TE, Sprecher DL, Tierney WM.

Am Heart J. 2006 Mar;151(3):755.e1-755.e6.

PMID:
16504648
45.

Elevated skin tissue cholesterol levels and myocardial infarction.

Sprecher DL, Pearce GL.

Atherosclerosis. 2005 Aug;181(2):371-3.

PMID:
16039292
46.

Effect of cooling and seminal plasma on the capacitation status of fresh boar sperm as determined using chlortetracycline assay.

Vadnais ML, Kirkwood RN, Tempelman RJ, Sprecher DJ, Chou K.

Anim Reprod Sci. 2005 Jun;87(1-2):121-32. Epub 2004 Dec 22.

PMID:
15885445
47.

C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s.

Henry K, Kitch D, Dube M, Zackin R, Parker RA, Sprecher D, Hammer S, Currier J; Adult AIDS Clinical Trials Group.

AIDS. 2004 Dec 3;18(18):2434-7. No abstract available.

PMID:
15622323
48.

Impact of nonprescriptive factors on low-density lipoprotein cholesterol reduction with statins.

Frolkis JP, Pearce GL, Sprecher DL.

Am J Cardiol. 2004 Nov 15;94(10):1310-2.

PMID:
15541255
50.

Relation of homocysteine and C-reactive protein to urinary albumin loss.

Seshadri N, Messerli AW, Acharya N, Pearce GL, Jacobsen DW, Pohl MA, Robinson K, Sprecher DL.

Am J Cardiol. 2004 Apr 1;93(7):926-8.

PMID:
15050501

Supplemental Content

Loading ...
Support Center